Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Thyroid Neoplasms 1Neuroendocrine Tumors 1Glioma 1Carcinoma, Medullary 1Brain Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

lutetium Lu 177 dotatate 15Everolimus 11Nivolumab 10pembrolizumab 9Temozolomide 9Capecitabine 7cabozantinib 6Sunitinib 6lenvatinib 5lanreotide 4gallium Ga 68 dotatate 4Ipilimumab 4Etoposide 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3pazopanib 3avelumab 3Octreotide 3Magnetic Resonance Spectroscopy 3Injections 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3surufatinib 2sintilimab 2fosbretabulin 2fludarabine 2Specimen Handling 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroendocrine Tumors × Lithium Carbonate × Clear all
NCT00501540 2019-11-26

Lithium for Low-Grade Neuroendocrine Tumors

University of Wisconsin, Madison

Phase 2 Completed
15 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡